NCT06344533View on ClinicalTrials.gov

Study of JMKX003142 Injection in Chinese Healthy Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

April 10, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

May 30, 2025

Conditions
Healthy Adult
Interventions
DRUG

JMKX003142 Injection

JMKX003142 Injection will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.

DRUG

Placebo

Matching placebo will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.

Trial Locations (1)

100191

Peking University Third Hospital, Beijing

Sponsors

Lead Sponsor

Jemincare
All Listed Sponsors
collaborator

Zhejiang Hangyu Pharmaceutical Co., Ltd.

INDUSTRY

lead

Jemincare

INDUSTRY

NCT06344533 - Study of JMKX003142 Injection in Chinese Healthy Subjects | Biotech Hunter | Biotech Hunter